

Table I-14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race/Ethnicity and Sex

17 SEER Areas, 2001-2003

Site	All Races		Whites		Blacks		Asian/Pacific Islanders		Hispanics <sup>a</sup>	
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females
All Sites	45.31	37.86	45.28	38.88	42.67	32.25	39.99	32.65	40.95	33.30
Invasive and In Situ	47.21	41.69	47.28	42.84	43.36	34.84	40.92	35.65	42.01	35.80
Oral Cavity and Pharynx	1.39	0.66	1.41	0.66	1.26	0.53	1.11	0.66	0.96	0.47
Esophagus	0.76	0.25	0.78	0.24	0.82	0.30	0.51	0.16	0.62	0.22
Stomach	1.12	0.68	1.01	0.57	1.31	0.99	2.44	1.72	1.80	1.36
Colon and Rectum	5.79	5.37	5.79	5.34	5.17	5.41	6.16	5.50	5.03	4.48
Invasive and In Situ	6.14	5.64	6.14	5.61	5.51	5.73	6.50	5.74	5.30	4.71
Liver and Intrahepatic Bile Duct	0.88	0.40	0.74	0.34	0.92	0.36	2.46	1.19	1.46	0.76
Pancreas	1.27	1.27	1.29	1.25	1.18	1.46	1.28	1.31	1.18	1.54
Larynx	0.63	0.15	0.62	0.15	0.86	0.18	0.43	0.04	0.60	0.09
Invasive and In Situ	0.68	0.16	0.67	0.17	0.90	0.19	0.43	0.04	0.62	0.09
Lung and Bronchus	8.02	6.15	8.09	6.47	8.26	5.21	7.07	4.18	5.21	3.36
Melanoma of the Skin	2.04	1.38	2.33	1.60	0.08	0.09	0.19	0.14	0.45	0.49
Invasive and In Situ	3.26	2.25	3.69	2.59	0.09	0.11	0.25	0.20	0.66	0.71
Breast	0.12	12.67	0.12	13.25	0.14	9.98	0.08	9.34	0.06	9.23
Invasive and In Situ	0.13	15.16	0.13	15.80	0.16	11.91	0.08	11.69	0.07	10.82
Cervix Uteri	-	0.73	-	0.69	-	0.94	-	0.82	-	1.22
Corpus and Uterus, NOS	-	2.49	-	2.61	-	1.93	-	1.72	-	1.89
Invasive and In Situ	-	2.52	-	2.64	-	1.96	-	1.74	-	1.91
Ovary <sup>b</sup>	-	1.44	-	1.53	-	0.95	-	1.12	-	1.35
Prostate	17.12	-	16.58	-	19.76	-	12.62	-	16.29	-
Testis	0.36	-	0.42	-	0.10	-	0.11	-	0.26	-
Urinary Bladder(Invasive and In Situ)	3.61	1.14	3.95	1.22	1.40	0.78	2.22	0.67	2.34	0.84
Kidney and Renal Pelvis	1.65	0.97	1.72	1.01	1.46	0.91	1.01	0.58	1.68	1.09
Brain and Other Nervous System	0.65	0.52	0.71	0.57	0.34	0.31	0.41	0.30	0.55	0.51
Thyroid	0.36	1.02	0.38	1.06	0.17	0.59	0.40	1.12	0.30	1.02
Hodgkin Lymphoma	0.24	0.20	0.26	0.21	0.19	0.15	0.13	0.10	0.27	0.15
Non-Hodgkin Lymphoma	2.14	1.83	2.24	1.92	1.25	1.07	1.91	1.60	1.96	1.77
Myeloma	0.67	0.53	0.63	0.49	1.06	0.89	0.45	0.43	0.77	0.63
Leukemia	1.49	1.05	1.56	1.10	0.94	0.76	1.01	0.72	1.19	0.93
Acute Lymphocytic Leukemia	0.13	0.11	0.14	0.11	0.06	0.05	0.12	0.13	0.18	0.16
Chronic Lymphocytic Leukemia	0.53	0.34	0.57	0.36	0.31	0.22	0.13	0.09	0.30	0.17
Acute Myeloid Leukemia	0.44	0.33	0.45	0.34	0.29	0.24	0.43	0.31	0.39	0.35
Chronic Myeloid Leukemia	0.18	0.13	0.18	0.13	0.14	0.11	0.15	0.09	0.15	0.11
Kaposi Sarcoma	0.10	0.02	0.08	0.01	0.16	0.01	0.06	0.00	0.14	0.04
Mesothelioma	0.20	0.05	0.23	0.06	0.08	0.02	0.09	0.02	0.20	0.07

Devcan Version 6.1.0, April 2006, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>a</sup> Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from Hawaii, Seattle, Alaska Native Registry and Kentucky.<sup>b</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Note: Invasive cancer only unless specified otherwise.